<i>TP53/KRAS</i> variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas
These results suggest that VAF ratios and concurrent mutations can be incorporated into multimodality assessments of pancreatic cysts. Longitudinal studies in patients with a lower initial TP53 VAF ratio are warranted to elucidate whether serial VAF ratios are more accurate markers than a single VAF measurement.
Authors
- Ralph H. Hruban (ORCID: https://orcid.org/0000-0003-4554-5672)
- Syed Z. Ali (ORCID: https://orcid.org/0000-0002-9069-8427)
- Elham Afghani (ORCID: https://orcid.org/0000-0002-9014-9735)
- Kelly J. Lafaro (ORCID: https://orcid.org/0000-0002-7070-7269)
- Laura DeLong Wood (ORCID: https://orcid.org/0000-0003-3096-652X)
- Marcia Irene Canto (ORCID: https://orcid.org/0000-0002-2193-3032)
- James R. Eshleman (ORCID: https://orcid.org/0000-0002-9274-8459)
- Jin Peng He (ORCID: https://orcid.org/0000-0001-9149-2247)
- Jing Zhu (ORCID: https://orcid.org/0000-0002-0665-1264)
- Ming-Tseh Lin
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1093/ajcp/aqaf133
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00